Bictegravir/emtricitabine/tenofovir alafenamide combination in the management of kidney transplant patients with HIV receiving immunosuppressants

Lagoutte-Renosi, Jennifer; Flammang, Mylène; Ducloux, Didier; Bamoulid, Jamal; Royer, P; Lepiller, Quentin; Clairet, Anne-Laure; Davani, Siamak; Muret, Patrice

doi:10.1080/1120009x.2021.1940436

Cited by 3 publications

(3 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent case report in a KT recipient with HIV described the utility of bictegravir/emtricitabine/tenofovir. 24 Novel injectable long-acting combination therapies including cabotegravir and rilpivirine have recently been approved by the Federal Drug Administration (FDA); data on the safety and efficacy of these novel compounds in KT recipients with HIV are warranted. 25 Strengths of this analysis include the granular real-world data that was captured including induction therapy dosing, ARV regimens, and modifications to these regimens over time.…”

Section: Adjusted Hr Of Acute Rejection P-valuementioning

confidence: 99%

Influence of induction therapy and antiretroviral regimen on outcomes in kidney transplant recipients living with human immunodeficiency

Marks,

Durand,

Bowring

et al. 2024

Transplant Infectious Dis

View full text Add to dashboard Cite

PurposeKidney transplantation has a survival benefit for people with human immunodeficiency virus (HIV) and end‐stage kidney disease, however increased rates of rejection remain an issue. Questions remain regarding the impact of induction immunosuppression therapy and antiretroviral (ARV) choice on long‐term outcomes.MethodsWe performed a multicenter retrospective analysis of outcomes in recipients with HIV who received kidneys from donors without HIV transplanted between 2004 and 2019. The association between induction and ARV regimens and long‐term outcomes including rejection, graft, and recipient survival over 5 years was investigated using Cox regression modeling.ResultsSeventy‐eight kidney transplants (KT) performed in 77 recipients at five US transplant centers were included, with median follow up of 7.1 (4.3–10.7) years. Overall recipient and graft survival were 83% and 67%, respectively. Rejection occurred in 37% (29/78). Recipients with rejection were more likely to be younger, recipients of deceased donor organs, and Black. Receipt of rabbit anti‐thymocyte globulin (rATG) induction without protease‐inhibitor (PI)‐based ARVs was associated with 83% lower risk of rejection (adjusted hazard ratio (aHR) 0.17 (95% CI 0.05–0.63), p =.007) and a non‐statistically significantly lower risk of graft failure (aHR 0.18 (0.03–1.16), p =.07) when compared to those who received other induction and ARV combinations.ConclusionsIn this multicenter retrospective study, we found a trend toward lower rejection and improved graft survival among those who received both rATG for induction and PI‐sparing ARVs. image

show abstract

Section: Adjusted Hr Of Acute Rejection P-valuementioning

confidence: 99%

Influence of induction therapy and antiretroviral regimen on outcomes in kidney transplant recipients living with human immunodeficiency

Marks,

Durand,

Bowring

et al. 2024

Transplant Infectious Dis

View full text Add to dashboard Cite

show abstract

“…Ideally, ART regimens should be modified to avoid significant drug-drug interactions to ensure these patients are optimally treated for their respective cancer or organ dysfunction. 38 An example of this modification was described in a case report where there was an expected drug interaction between tacrolimus and a boosted protease inhibitor (PI) in a transplant recipient. 38 Though tacrolimus dosing was adjusted to account for the anticipated pharmacokinetic reactions, a tacrolimus overdose occurred.…”

Section: Other Treatment Options For Hiv/hepatitis B Virus Co-infectionmentioning

confidence: 99%

“…38 An example of this modification was described in a case report where there was an expected drug interaction between tacrolimus and a boosted protease inhibitor (PI) in a transplant recipient. 38 Though tacrolimus dosing was adjusted to account for the anticipated pharmacokinetic reactions, a tacrolimus overdose occurred. The case report highlighted the importance of not allowing a sufficient timeframe of withdrawal of a PI when drug interactions are expected.…”

Section: Other Treatment Options For Hiv/hepatitis B Virus Co-infectionmentioning

confidence: 99%

Bictegravir/Emtricitabine/Tenofovir Alafenomide for the Treatment of HIV/Hepatitis B Virus Co-infection in Patients with Cancer and Transplant Recipients

Dickter,

Ross

2023

Infectious Diseases

View full text Add to dashboard Cite

For people with HIV/hepatitis B virus (HBV) co-infection who develop comorbidities that require polypharmacy, treatment may be complicated due to drug interactions and overlapping toxicities of medications received. As the population with HIV ages, there are more patients developing malignancies and undergoing transplantation, and management can be complicated. This review describes the best strategies for the treatment of a hypothetical patient with HIV/HBV co-infection who develops diffuse large B-cell lymphoma and ultimately undergoes autologous haematopoietic stem cell transplantation. In this theoretical case, the patient is treated with bictegravir/emtricitabine/tenofovir alafenamide. Situations arise where people with HIV have underlying antiretroviral drug resistance and HBV drug resistance that require optimization of their antiviral therapy. As these types of cases are seen commonly at our institution, we discuss special situations that develop during treatment, including immune reconstitution inflammatory syndrome, that require close monitoring and occasional treatment modifications during their course of therapy.

show abstract

Multiple drugs

2021

Reactions Weekly

View full text Add to dashboard Cite

Bictegravir/emtricitabine/tenofovir alafenamide combination in the management of kidney transplant patients with HIV receiving immunosuppressants

Cited by 3 publications

References 20 publications

Influence of induction therapy and antiretroviral regimen on outcomes in kidney transplant recipients living with human immunodeficiency

Influence of induction therapy and antiretroviral regimen on outcomes in kidney transplant recipients living with human immunodeficiency

Bictegravir/Emtricitabine/Tenofovir Alafenomide for the Treatment of HIV/Hepatitis B Virus Co-infection in Patients with Cancer and Transplant Recipients

Multiple drugs

Contact Info

Product

Resources

About